Jayaraj Arjun, Thaggard David, Lucas Michael
RANE Center for Venous and Lymphatic Diseases, St. Dominic Hospital, Jackson, MS.
RANE Center for Venous and Lymphatic Diseases, St. Dominic Hospital, Jackson, MS.
J Vasc Surg Venous Lymphat Disord. 2023 May;11(3):634-641. doi: 10.1016/j.jvsv.2022.12.067. Epub 2023 Jan 31.
Femoroiliocaval stenting has become the standard of care for patients with quality-of-life impairing chronic iliofemoral venous obstruction not responding to conservative measures. Although improvement after stenting has been noted in multiple large studies, sizing of stents has been subjective in nature with a general tendency to use smaller stents that would be required to relieve venous hypertension. This study evaluates the authors' technique of using the intravascular ultrasound (IVUS) inflow channel luminal area to guide stent sizing.
Patients who underwent femoroiliocaval stenting for quality-of-life impairing chronic iliofemoral venous obstruction and had failed conservative therapy from 2015 to 2021 were included in the study. Clinical outcomes including venous clinical severity score (VCSS), visual analog scale (VAS) pain score, and grade of swelling (GOS) were appraised before and after stenting. Also evaluated were quality of life (Chronic Venous Insufficiency Questionnaire-20 [CIVIQ-20] instrument) and stent outcomes including patencies and reinterventions. Comparisons were made between limbs that underwent placement of larger caliber stents (largest stent diameter >20 mm: >20 mm stent group) vs smaller caliber stents (largest stent diameter ≤20 mm: ≤20 mm stent group). t tests and analysis of variance were used to compare outcomes, whereas the Kaplan-Meier analysis was used to evaluate patencies with log rank used to compare the curves.
A total of 300 patients (300 limbs) underwent stenting with a median age of 58 years. There was a preponderance of men (159 of 300), left laterality (176 of 300), and post-thrombotic syndrome (176 of 300). The median body mass index was 41. There were 120 limbs in the >20 mm stent group and 180 limbs in the ≤20 mm stent group. The median follow-up was 23 months. There was no significant difference in baseline VCSS, VAS pain score, or GOS between the two groups. However, there was a significant difference in IVUS-determined inflow channel luminal area between the two groups (228 mm >20 mm stent group vs 176 mm for ≤20 mm stent group [P < .0001]). After stenting there was a significant improvement in the VCSS, VAS pain score, and GOS at 6 weeks, 3, 6, 12, and 24 months (P < .0001) without any difference between the groups (P > .05). The CIVIQ-20 score also improved from 58 to 38 (P < .0001) for the entire cohort and for the two groups (P < .0001). Overall primary, primary-assisted, and secondary patencies at 60 months were 84%, 100%, and 100%, respectively. Reintervention rate was 10% without any difference between the groups.
Stent sizing using IVUS-determined inflow channel luminal area in patients undergoing stenting for quality-of-life impairing chronic iliofemoral venous obstruction resulted in a significant improvement in the VCSS, VAS pain score, GOS, and quality of life (CIVIQ-20) after stenting. Excellent stent patencies and low reintervention rates were also noted. IVUS-determined inflow channel luminal area represents an objective technique of stent sizing in comparison to the subjective techniques that currently exist.
对于因慢性髂股静脉阻塞而生活质量受损且保守治疗无效的患者,股髂腔静脉支架置入术已成为标准治疗方法。尽管多项大型研究已表明支架置入术后病情有所改善,但支架尺寸的选择一直具有主观性,总体倾向于使用小于缓解静脉高压所需尺寸的支架。本研究评估了作者使用血管内超声(IVUS)流入道管腔面积来指导支架尺寸选择的技术。
纳入2015年至2021年因慢性髂股静脉阻塞导致生活质量受损而接受股髂腔静脉支架置入术且保守治疗失败的患者。评估支架置入前后的临床结局,包括静脉临床严重程度评分(VCSS)、视觉模拟量表(VAS)疼痛评分和肿胀分级(GOS)。还评估了生活质量(慢性静脉功能不全问卷-20 [CIVIQ-20] 工具)以及支架结局,包括通畅率和再次干预情况。对接受较大口径支架置入的肢体(最大支架直径>20 mm:>20 mm支架组)与较小口径支架置入的肢体(最大支架直径≤20 mm:≤20 mm支架组)进行比较。采用t检验和方差分析比较结局,而采用Kaplan-Meier分析评估通畅率,并使用对数秩检验比较曲线。
共有300例患者(300条肢体)接受了支架置入术,中位年龄为58岁。男性居多(300例中有159例),左侧病变居多(300例中有176例),血栓形成后综合征患者居多(300例中有176例)。中位体重指数为41。>20 mm支架组有120条肢体,≤20 mm支架组有180条肢体。中位随访时间为23个月。两组之间的基线VCSS、VAS疼痛评分或GOS无显著差异。然而,两组之间IVUS测定的流入道管腔面积存在显著差异(>20 mm支架组为228 mm²,≤20 mm支架组为176 mm² [P <.0001])。支架置入后6周、3个月、6个月、12个月和24个月时,VCSS、VAS疼痛评分和GOS均有显著改善(P <.0001),两组之间无差异(P >.05)。整个队列以及两组的CIVIQ-20评分也从58分提高到了38分(P <.0001)。60个月时的总体原发性、原发性辅助性和继发性通畅率分别为84%、100%和100%。再次干预率为10%,两组之间无差异。
对于因慢性髂股静脉阻塞导致生活质量受损而接受支架置入术的患者,使用IVUS测定的流入道管腔面积来确定支架尺寸可使支架置入术后的VCSS、VAS疼痛评分、GOS和生活质量(CIVIQ-20)得到显著改善。还观察到了出色的支架通畅率和较低的再次干预率。与目前存在的主观技术相比,IVUS测定的流入道管腔面积代表了一种客观的支架尺寸选择技术。